Xu Hao-Ming, Huang Hong-Li, Xu Jing, He Jie, Zhao Chong, Peng Yao, Zhao Hai-Lan, Huang Wen-Qi, Cao Chuang-Yu, Zhou Yong-Jian, Zhou You-Lian, Nie Yu-Qiang
Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Front Microbiol. 2021 Apr 12;12:658292. doi: 10.3389/fmicb.2021.658292. eCollection 2021.
Fecal microbiota transplantation (FMT) can inhibit the progression of ulcerative colitis (UC). However, how FMT modulates the gut microbiota and which biomarker is valuable for evaluating the efficacy of FMT have not been clarified. This study aimed to determine the changes in the gut microbiota and their relationship with butyric acid following FMT for UC. Fecal microbiota (FM) was isolated from healthy individuals or mice and transplanted into 12 UC patients or colitis mice induced by dextran sulfate sodium (DSS). Their clinical colitis severities were monitored. Their gut microbiota were analyzed by 16S sequencing and bioinformatics. The levels of fecal short-chain fatty acids (SCFAs) from five UC patients with recurrent symptoms after FMT and individual mice were quantified by liquid chromatography-mass spectrometry (LC-MS). The impact of butyric acid on the abundance and diversity of the gut microbiota was tested The effect of the combination of butyric acid-producing bacterium and FMT on the clinical responses of 45 UC patients was retrospectively analyzed. Compared with that in the controls, the FMT significantly increased the abundance of butyric acid-producing bacteria and fecal butyric acid levels in UC patients. The FMT significantly increased the α-diversity, changed gut microbial structure, and elevated fecal butyric acid levels in colitis mice. Anaerobic culture with butyrate significantly increased the α-diversity of the gut microbiota from colitis mice and changed their structure. FMT combination with -containing probiotics significantly prolonged the UC remission in the clinic. Therefore, fecal butyric acid level may be a biomarker for evaluating the efficacy of FMT for UC, and addition of butyrate-producing bacteria may prolong the therapeutic effect of FMT on UC by changing the gut microbiota.
粪菌移植（FMT）可抑制溃疡性结肠炎（UC）的进展。然而，FMT如何调节肠道微生物群以及哪种生物标志物对评估FMT的疗效有价值尚未明确。本研究旨在确定UC患者接受FMT后肠道微生物群的变化及其与丁酸的关系。从健康个体或小鼠中分离粪便微生物群（FM），并将其移植到12例UC患者或由葡聚糖硫酸钠（DSS）诱导的结肠炎小鼠中。监测其临床结肠炎严重程度。通过16S测序和生物信息学分析其肠道微生物群。采用液相色谱-质谱联用（LC-MS）对5例FMT后复发症状的UC患者和个体小鼠的粪便短链脂肪酸（SCFA）水平进行定量。测试丁酸对肠道微生物群丰度和多样性的影响。回顾性分析产丁酸菌与FMT联合应用对45例UC患者临床反应的影响。与对照组相比，FMT显著增加了UC患者中产丁酸菌的丰度和粪便丁酸水平。FMT显著增加了结肠炎小鼠的α多样性，改变了肠道微生物结构，并提高了粪便丁酸水平。用丁酸盐进行厌氧培养显著增加了结肠炎小鼠肠道微生物群的α多样性并改变了其结构。FMT与含益生菌联合应用在临床上显著延长了UC的缓解期。因此，粪便丁酸水平可能是评估FMT治疗UC疗效的生物标志物，添加产丁酸菌可能通过改变肠道微生物群来延长FMT对UC的治疗效果。
